IRIS
THELLUNG DE COURTELARY, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.277
Totale 8.277
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 8.277
Totale 8.277
Salva come PNG Salva come JPEG
Città #
Genova 6.524
Rapallo 897
Genoa 828
Bordighera 27
Totale 8.276
Salva come PNG Salva come JPEG
Nome #
Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death 152
Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm 149
Amyloid precursor protein modulates ERK1/2 signaling 149
Calcium binding promotes Prion Protein fragment 90-231 conformational change toward a membrane destabilizing and cytotoxic structure 149
Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells 148
Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231 146
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors 146
Characterization of the pro-apoptotic intracellular mechanisms induced by a toxic conformer of the recombinant human prion protein fragment 90-231 141
Apoptotic cell death and impairment of L-type voltage sensitive calcium channel activity in rat cerebellar granule cells treated with the prion protein fragment 106-126 141
Amyloid precursor protein and Presenilin 1 interaction studied by FRET in human H4 cells. 139
Basic fibroblast growth factor activates endothelial nitric-oxide synthase in CHO-K1 cells via the activation of ceramide synthesis 138
Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: involvement of A2, purinergic receptor subtypes 136
SDF1 controls pituitary cell proliferation through the activation of ERK1/2 and the Ca2+-dependent cytosolic tyrosine kinase, Pyk2. 129
Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma 128
Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds 128
Novel celecoxib analogues inhibit glial production of prostaglandinE2, nitric oxide, and oxygen radicals reverting the neuroinflammatoryresponses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide 127
p38 MAP Kinase mediates the cell death induced by PrP106-126 in the SH-SY5Y neuroblastoma cells 120
Different Molecular Mechanisms Mediate Direct or Glia-Dependent Prion Protein Fragment 90–231 Neurotoxic Effects in Cerebellar Granule Neurons 119
Prion protein fragment 106-126 induces a p38 MAP kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid fibril formation 118
Different structural stability and toxicity of PrPARR and PrPARQ sheep prion protein variants 117
Ruta graveolens L. induces death of glioblastoma cells and neural progenitors, but not of neurons, via ERK 1/2 and AKT activation 117
Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells 117
In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity 116
Amino-terminally truncated prion protein PrP90-231 induces microglial activation in vitro 115
Excitotoxicity Through NMDA Receptors Mediates Cerebellar Granule Neuron Apoptosis Induced by Prion Protein 90-231 Fragment 115
Molecular pharmacology of malignant pleural mesothelioma: Challenges and perspectives from preclinical and clinical studies 114
Human PrP90-231-induced cell death is associated with intracellular accumulation of insoluble and protease-resistant macroaggregates and lysosomal dysfunction 113
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 113
Conformation dependent pro-apoptotic activity of the recombinant human prion protein fragment 90-231 113
Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line. 111
Role of prion protein aggregation in neurotoxicity 111
Expression in E. coli and purification of recombinant fragments of wild type and mutant human prion protein 111
In silico identification and experimental validation of novel anti-Alzheimer's multitargeted ligands from marine source featuring a "2-amino-imidazole plus aromatic group" scaffold 111
High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein 110
Isolation of stem-like cells from spontaneous feline mammary carcinomas: phenotypic characterization and tumorigenic potential 106
In vitro study of uptake and synthesis of creatine and its precursors by cerebellar granule cells and astrocytes suggests some hypotheses on the physiopathology of the inherited disorders of creatine metabolism 106
Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2 105
Chemokine stromal cell-derived factor 1α induces proliferation and growth hormone release in GH4C1 rat pituitary adenoma cell line through multiple intracellular signals 103
The chemokine SDF1/CXCL12: a novel autocrine/paracrine factor involved in pituitary adenoma development 102
ERK1/2 and p38 MAP kinases control prion protein fragment 90-231-induced astrocyte proliferation and microglia activation 101
Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity 101
Molecular mechanisms mediating neuronal cell death in experimental models of prion diseases, in vitro 100
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 99
Canine osteosarcoma cell lines contain stem-like cancer cells: Biological and pharmacological characterization 95
Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity 94
Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity 94
INTRACELLULAR MECHANISMS MEDIATING THE NEURONAL CELL DEATH AND ASTROGLIOSIS INDUCED BY THE PRION PROTEIN FRAGMENT 106-126 93
CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis 93
Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor 3 (SSTR3) mediated regulation of endothelial NOS and MAP kinase activities” 92
Nitric oxide production stimulated by the basic fibroblast growth factor requires the synthesis of ceramide 92
TGF-beta1 prevents gp120-induced impairment of Ca++ homeostasis and rescues cortical neurons from apoptotic death 91
A. novel mechanism for the melatonin inhibition of testosterone secretion by rat Leydig cells: reduction of GnRH-induced cytosolic Ca2+ rise 91
Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling 91
Emerging Role of Cellular Prion Protein in the Maintenance and Expansion of Glioma Stem Cells 88
Consensus based recommendations for diagnosis and medical management of Poland syndrome (sequence) 88
Aminoterminally truncated human Prion protein fragment 90-231 forms intracellular aggregates and causes lysosomal loss of impermeability 87
Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90-231 (hPrP90-231), as possible mechanism of its neurotoxic effects 86
Identification of a conserved N-capping box important for the structural autonomy of the prion alpha 3-helix: the disease associated D202N mutation destabilizes the helical conformation 84
Oncogene transformation of PC Cl3 clonal thyroid cell line induces an autonomous pattern of proliferation that correlates with a loss of basal and stimulated phosphotyrosine phosphatase activity 84
Molecular mechanisms involved in the aggregation and fibril formation of the recombinant human prion fragment PrP90-231 83
Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells 78
Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives 78
Addressing thermal and mechanical stability of human prion protein with single molecule and ensemble measurements 76
Effect of nitric Oxide Donors on GABA Uptake by Rat Brain Synaptosomes. Neurochem. Research 75
Intracellular transducing mechanisms modulated by activated brain somatostatin receptors 74
Synthesis of guanidinoacetate and creatine in neurons and glial cells 73
Prion protein fragment 90-231 induces microglia activation: role of ERK1/2 and p38 MAP kinases in nitric oxide production and CCL5 secretion 73
Prolonged treatment with alpha-glycerylphosphorylethanolamine facilitates the acquisition of an active avoidance behavior and selectively increases neuronal signal transduction in rats 72
Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro 71
Somatostatin controls Kaposi sarcoma growth through inhibition of angiogenesis 70
The activation of the phosphotyrosine phosphatase h (r-PTPh) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation 69
Celecoxib, a COX-2 inhibitor, blocks microglial activation induced by a neurotoxic conformer of hPrP90-231 69
ACTIVATION OF AUTOPHAGY PATHWAY AS NEUROPROTECTIVE MECHANISM AGAINST AMYLOIDOGENIC PRION PEPTIDE 69
Identification of the hydantoin alkaloids parazoanthines as novel CXCR4 antagonists by computational and in vitro functional characterization 67
Somatostatinergic control of Kaposi’s sarcoma growth through the inhibition of angiogenesis 66
MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment 66
Nitric Oxide and GABAA Receptor Function in the Rat Cerebral Cortex and Cerebellar Granule Cells. 65
Expression of somatostatin receptors mRNA in human meningiomas and their implication in in vitro antiproliferative activity 64
Neurotoxicity of the recombinant prion protein fragment 90-231 in SH-SY5Y cells is dependent on its conversion in beta-structured-isoform 63
Study of the Molecular Mechanism Responsible of the Conformational Changes Induced by E200K and D202N Pathological PrP Mutation 63
Molecular mechanisms mediating the neuroprotective effects of quinacrine and minocycline on cell death induced by the prion protein fragment 90-231 (hPrP90-231) 61
Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies 61
Study of the molecular mechanisms responsible of the transition of the prion protein fragment 90-231 in a neurotoxic conformation. 53
Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity 44
The activation of the phosphotyrosine phosphatase eta is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation 38
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 34
Development and validation of a GC-MS method for determination of metformin in normal brain and in glioblastoma tissues 26
Proteostasis unbalance in prion diseases: mechanisms of neurodegeneration and therapeutic targets 21
Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro 10
Bioinspired nanoparticles for glioblastoma treatment 8
Prolonged treatment with α-glycerylphosphorylethanolamine facilitates the acquisition of an active avoidance behavior and selectively increases neuronal signal transduction in rats 1
Totale 8.514
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.210
article - articoli 23.099
book - libri 0
conference - conferenze 660
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 451
Totale 48.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.181 74 50 75 130 208 269 329 172 196 347 258 73
2020/2021798 50 86 76 64 87 58 48 72 56 104 52 45
2021/20221.107 35 102 62 119 36 87 87 249 41 86 53 150
2022/20231.064 91 63 9 107 168 183 1 95 170 6 156 15
2023/2024668 45 71 16 89 45 151 44 39 28 24 44 72
2024/202529 29 0 0 0 0 0 0 0 0 0 0 0
Totale 8.514